This is a federal contract award to Telix Pharmaceuticals US Inc., a global biopharmaceutical company, by the U.S. Department of Veterans Affairs (VA) through its Veterans Health Administration (VHA). The contract, with a ceiling value of $858,000.00, is for the delivery of various radiopharmaceuticals to support the VA's nuclear medicine and medical imaging services for veterans.
The contract is a Blanket Purchase Agreement (BPA) call order awarded under a larger $17.5 million BPA the company holds with the VA National Acquisition Center, as well as a separate $4.55 million BPA with VISN 9 (Veterans Integrated Service Network 9) for radiopharmaceutical supplies through 2028. These contract vehicles allow the VA to efficiently procure Telix's radiopharmaceutical products, including Illuccix for prostate cancer imaging and Gozetotide for other nuclear medicine procedures, to fulfill the imaging and nuclear medicine needs across the VA healthcare system. The contract has a firm fixed price pricing type and does not have a small business set-aside designation.
Generated 10/16/24, 9:15 AM